What changed
Adjusted EPS of $2.11 topped the $1.92 consensus by $0.19, a 10.0% beat. Revenue came in at $6,554M, up 8.3% YoY, with core revenue up 3.0% and core ex-respiratory up 5.5%. Management raised FY2026 adjusted EPS guidance to $8.57–$8.62 from $8.45–$8.60 and guided Q4 FY26 adjusted operating margin to 29.5%. The print was fueled by accelerating core growth ex-respiratory plus DBS-driven execution, though respiratory testing was a 2.5% core headwind in the quarter.
Why it matters
Adjusted EPS of $2.11 topped the $1.92 consensus by $0.19, a 10.0% beat. Revenue came in at $6,554M, up 8.3% YoY, with core revenue up 3.0% and core ex-respiratory up 5.5%. Management raised FY2026 ad